A study published in the journal Diabetes, Obesity and Metabolism found that patients on once-weekly semaglutide experienced significant decreases in serum B12 levels alongside reductions in zinc and albumin
In the ACHIEVE-3 head-to-head trial published in The Lancet in February 2026, orforglipron 36 mg delivered 73.6% greater relative weight loss than oral semaglutide (14 mg) in people with type 2 diabetes 9.2% body weight loss vs
Non-Surgical Treatments Non-surgical therapies are often sufficient to manage spinal stenosis symptoms, especially if you seek treatment early
Unfortunately, data is inconsistent among these studies, likely due to the different methodologies used between studies, making it difficult to provide firm conclusions
The most reliable approach for an individual patient is to work with a reputable provider, track your own progress (weight, appetite, side effects), and communicate regularly with your healthcare provider about your response to treatment
)
